ReAlta Life Sciences Gains EMA Orphan Drug Designation for Graft-Versus-Host Disease Treatment
ReAlta Life Sciences received European Medicines Agency Orphan Drug Designation for its drug pegtarazimod, advancing a novel dual-targeting treatment approach for steroid-refractory acute graft-versus-host disease that addresses critical unmet medical needs.
The European Medicines Agency has granted Orphan Drug Designation to ReAlta Life Sciences' RLS-0071 (pegtarazimod) for the treatment of Graft-versus-Host Disease, marking a significant regulatory milestone for the clinical-stage biopharmaceutical company. This designation follows the U.S. Food and Drug Administration's August 2024 granting of both Orphan Drug and Fast Track Designations for the same indication, validating the company's novel approach to addressing this life-threatening condition.
The EMA designation was supported by preliminary data from ReAlta's ongoing Phase 2 trial involving steroid-refractory Acute GvHD patients. The company is currently enrolling patients in its Phase 2, open-label clinical trial NCT06343792 at clinical sites in the United States, Germany, and Spain, with additional data expected in 2026. This regulatory recognition provides ReAlta with reduced fees, clinical protocol assistance, and potential market exclusivity in the European Union if approved.
David Marek, Chief Executive Officer of ReAlta, stated that the EMA designation represents a significant milestone in addressing the urgent unmet need in aGvHD and validates the company's dual-targeting approach to modulate both neutrophil and complement-mediated inflammation. The treatment's mechanism targets specific pathways driving tissue damage while preserving beneficial immune function, unlike broadly immunosuppressive approaches currently used.
Dr. Kenji Cunnion, Chief Medical Officer, emphasized that pegtarazimod addresses the neutrophil-driven disease process in patients with lower gastrointestinal aGvHD, which is particularly difficult to treat and carries the highest mortality rates. The drug works by selectively inhibiting complement activation at C1, as well as myeloperoxidase activity and neutrophil extracellular trap formation—key mechanisms that drive inflammatory cascade and tissue damage following hematopoietic stem cell transplantation.
The EMA grants Orphan Drug Designation to medicines intended for rare, life-threatening diseases affecting fewer than five in 10,000 people in the European Union. For ReAlta, this designation accelerates the development pathway for a treatment that could address a critical gap in care for patients suffering from this devastating complication of stem cell transplantation.